Pharmacoeconomic advantages of recombinant FSH vs urinary derived FSH

Gynécologie, obstétrique & fertilité
Ariel Beresniak

Abstract

Nowadays, the use of urinary FSH is essentially justified by a lower acquisition price compared to modern products generated by Biotechnology (recombinant FSH). However, the public price of a product is only one element of the total cost of a therapeutic regimen that must be taken into account in medical decision-making. This is the role of pharmacoeconomic studies including cost-effectiveness models, which allow proceeding to complex situational comparisons such as several attempts of Assisted Reproduction Techniques. Different models have been carried out and published in several countries and present consistently that recombinant FSH is more cost-effective that urinary derived FSH.

References

Jan 1, 1985·Medical Decision Making : an International Journal of the Society for Medical Decision Making·P DoubiletB J McNeil
Mar 8, 1998·PharmacoEconomics·A Briggs, M Sculpher
Apr 30, 1999·Human Reproduction·L G MantovaniT D Szucs

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bioinformatics in Biomedicine

Bioinformatics in biomedicine incorporates computer science, biology, chemistry, medicine, mathematics and statistics. Discover the latest research on bioinformatics in biomedicine here.